Literature DB >> 9514054

Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.

M L Hauck1, R H Larsen, P C Welsh, M R Zalutsky.   

Abstract

The high linear energy transfer, alpha-particle-emitting radionuclide astatine-211 (211At) is of interest for certain therapeutic applications; however, because of the 55- to 70-microm path length of its alpha-particles, achieving homogeneous tracer distribution is critical. Hyperthermia may enhance the therapeutic efficacy of alpha-particle endoradiotherapy if it can improve tracer distribution. In this study, we have investigated whether hyperthermia increased the cytotoxicity of an 211At-labelled monoclonal antibody (MAb) in tumour spheroids with a radius (approximately 100 microm) greater than the range of 211At alpha-particles. Hyperthermia for 1 h at 42 degrees C was used because this treatment itself resulted in no regrowth delay. Radiolabelled chimeric MAb 81C6 reactive with the extracellular matrix antigen tenascin was added to spheroids grown from the D-247 MG human glioma cell line at activity concentrations ranging from 0.125 to 250 kBq ml(-1). A significant regrowth delay was observed at 125 and 250 kBq ml(-1) in both hyperthermia-treated and untreated spheroids. For groups receiving hyperthermia, no increase in cytotoxicity was seen compared with normothermic controls at any activity concentration. These results and those from autoradiographs indicate that hyperthermia at 42 degrees C for 1 h had no significant effect on the uptake or distribution of this antitenascin MAb in D-247 MG spheroids.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9514054      PMCID: PMC2149964          DOI: 10.1038/bjc.1998.123

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Elimination of dose-rate effects by mild hyperthermia.

Authors:  Z Wang; E P Armour; P M Corry; A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Enteraction of hyperthermia with radiations of different linerar energy transfer.

Authors:  E W Gerner; J T Leith
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1977-03

3.  Specific chromosomal abnormalities in malignant human gliomas.

Authors:  S H Bigner; J Mark; P C Burger; M S Mahaley; D E Bullard; L H Muhlbaier; D D Bigner
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

4.  The effects of hyperthermia on tumor carcinoembryonic antigen expression.

Authors:  J Y Wong; N F Mivechi; R J Paxton; L E Williams; B G Beatty; J D Beatty; J E Shively
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-10       Impact factor: 7.038

5.  Nonuniformity of tumor dose in radioimmunotherapy.

Authors:  J L Humm; L M Cobb
Journal:  J Nucl Med       Date:  1990-01       Impact factor: 10.057

6.  Enhancement of monoclonal antibody binding to melanoma with single dose radiation or hyperthermia.

Authors:  D R Stickney; D S Gridley; G A Kirk; J M Slater
Journal:  NCI Monogr       Date:  1987

Review 7.  Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection.

Authors:  L T Baxter; R K Jain
Journal:  Microvasc Res       Date:  1989-01       Impact factor: 3.514

8.  Mathematical model of simultaneous diffusion and binding of antitumor antibodies in multicellular human tumor spheroids.

Authors:  R McFadden; C S Kwok
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

9.  Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.

Authors:  J L Dangl; T G Wensel; S L Morrison; L Stryer; L A Herzenberg; V T Oi
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

10.  A tumour spheroid model for antibody-targeted therapy of micrometastases.

Authors:  K A Walker; T Murray; T E Hilditch; T E Wheldon; A Gregor; I M Hann
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

View more
  6 in total

1.  Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.

Authors:  Mengshi Li; Xiuli Zhang; Thomas P Quinn; Dongyoul Lee; Dijie Liu; Falk Kunkel; Brian E Zimmerman; Daniel McAlister; Keith Olewein; Yusuf Menda; Saed Mirzadeh; Roy Copping; Frances L Johnson; Michael K Schultz
Journal:  Appl Radiat Isot       Date:  2017-05-10       Impact factor: 1.513

Review 2.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

3.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

Review 4.  Targeted and Nontargeted α-Particle Therapies.

Authors:  Michael R McDevitt; George Sgouros; Stavroula Sofou
Journal:  Annu Rev Biomed Eng       Date:  2018-01-18       Impact factor: 9.590

5.  Transcriptional Response in Mouse Thyroid Tissue after 211At Administration: Effects of Absorbed Dose, Initial Dose-Rate and Time after Administration.

Authors:  Nils Rudqvist; Johan Spetz; Emil Schüler; Toshima Z Parris; Britta Langen; Khalil Helou; Eva Forssell-Aronsson
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

6.  Mild hyperthermia influence on Herceptin(®) properties.

Authors:  Jean-Michel Escoffre; Roel Deckers; Noboru Sasaki; Clemens Bos; Chrit Moonen
Journal:  Radiol Oncol       Date:  2015-03-03       Impact factor: 2.991

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.